You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
交银国际:重申石药集团(1093.HK)买入评级 目标价上调至11港元
格隆汇 03-16 12:35

交银国际发表研究报告表示,石药集团(1093.HK)公布去年盈利51.6亿元人民币,按年升38.9%,符合该行预期,该行预计石药2021至23年销售收入可录双位数复合年增长,将其目标价由10.57港元上调至11港元,重申买入评级。

报告指,石药创新药产品保持高速增长,肿瘤药销售收入为62.9亿元,其中多美素、津优力和克艾力销售收入分别增长41.3%、37.3%及16.4%;恩必普去年销售收入增长17.4%,预计2021-23年销售收入将会以双位数的复合增长率增长。

公司去年预研发投入28.9亿元,两性霉素B复合物、米托蒽醌脂质体预计将于今年上市。此外公司已取得CM310(抗IL-4R重组全人源抗体)及BPI-7711胶囊(第三代不可逆EGFR-TKI)的产品授权及商业化权利。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account